Allon’s Phase 1 Trial Suggests Davenutide is Safe

Allon’s preclinical studies and Phase 2a clinical trials have shown that davunetide is active in treating diseases known to have impaired tau function, including frontotemporal dementias. Given davunetide’s purported mechanism of action in stabilizing microtubules, davenutide has potential as an ALS therapeutic.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail